Source: European Medicines Agency (EU) Revision Year: 2021 Publisher: Teva B.V., Swensweg 5, 2031 GA Haarlem, The Netherlands
Kentera 3.9 mg/24 hours transdermal patch.
| Pharmaceutical Form |
|---|
|
Transdermal patch. The patch is a clear plastic with an adhesive backing, protected by a release liner that is to be removed prior to application. |
Each transdermal patch contains 36 mg of oxybutynin. The area of the patch is 39 cm², releasing a nominal 3.9 mg of oxybutynin per 24 hours.
For a full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Oxybutinin |
Oxybutynin acts as a competitive antagonist of acetylcholine at post-ganglionic muscarinic receptors, resulting in relaxation of bladder smooth muscle. |
| List of Excipients |
|---|
|
Backing film: Clear polyester/ethylene-vinyl acetate (PET/EVA) Middle layer: Triacetin Release liner: Siliconised polyester |
The transdermal patches are individually contained in LDPE/paper laminate sachets and supplied in Patient Calendar Boxes of 2, 8 or 24 patches.
Not all pack sizes may be marketed.
Teva B.V., Swensweg 5, 2031 GA Haarlem, The Netherlands
EU/1/03/270/001 8 transdermal patches
EU/1/03/270/002 24 transdermal patches
EU/1/03/270/003 2 transdermal patches
Date of first authorisation: 15 June 2004
Date of latest renewal: 30 April 2009
| Drug | Countries | |
|---|---|---|
| KENTERA | Austria, Estonia, Spain, Finland, France, Croatia, Ireland, Italy, Lithuania, Netherlands, Poland, Romania, Turkey, United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
